{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:58Z","timestamp":1787671858033,"version":"build-2736575974"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Potassium-competitive acid blockers (P-CABs) represent a major advancement in acid suppression by achieving rapid and sustained inhibition of gastric acid secretion. However, stronger acid suppression does not necessarily lead to better clinical outcomes. The clinical benefits of P-CABs vary according to the disease. In gastroesophageal reflux disease, P-CABs achieve healing rates for erosive esophagitis that are comparable to those of proton pump inhibitors (PPIs), with possible advantages in severe cases; however, consistent superiority in symptom control is lacking. The evidence for functional dyspepsia also remains insufficient. By contrast, in\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    eradication, P-CAB-based regimens have demonstrated clear advantages, particularly in the presence of antibiotic resistance. In peptic ulcer disease, the efficacy of P-CABs is comparable to that of PPIs. Long-term safety, including the effects of sustained hypergastrinemia, remains uncertain. Furthermore, symptom improvement and mucosal healing are not always concordant, thus highlighting the need to define therapeutic goals. Therefore, P-CABs should be used selectively on the basis of disease-specific requirements rather than pharmacological potency alone. An individualized approach is essential to optimize outcomes and avoid the unnecessary escalation of acid-suppressive therapy.\n                  <\/jats:p>","DOI":"10.1007\/s00535-026-02422-4","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:14:18Z","timestamp":1779171258000},"page":"1187-1206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving landscape of potassium-competitive acid blockers: toward disease-specific use beyond acid suppression"],"prefix":"10.1007","volume":"61","author":[{"given":"Hideki","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-6163","authenticated-orcid":false,"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2422_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022. Aug 8:gutjnl-2022-327745.\u00a0https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","journal-title":"Gut"},{"issue":"4","key":"2422_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","volume":"57","author":"K Iwakiri","year":"2022","unstructured":"Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267\u201385.","journal-title":"J Gastroenterol"},{"issue":"4","key":"2422_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00535-021-01769-0","volume":"56","author":"T Kamada","year":"2021","unstructured":"Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol. 2021;56(4):303\u201322.","journal-title":"J Gastroenterol"},{"issue":"3","key":"2422_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00535-017-1407-1","volume":"53","author":"H Suzuki","year":"2018","unstructured":"Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53(3):354\u201361.","journal-title":"J Gastroenterol"},{"issue":"6","key":"2422_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2422_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.5009\/gnl220373","volume":"17","author":"A Sawada","year":"2023","unstructured":"Sawada A, Sifrim D, Fujiwara Y. Esophageal reflux hypersensitivity: a comprehensive review. Gut Liver. 2023;17(6):831\u201342.","journal-title":"Gut Liver"},{"issue":"4","key":"2422_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00535-023-01966-z","volume":"58","author":"M Kato","year":"2023","unstructured":"Kato M, Hosoe N, Gotoda T, Kusano C, Kuramochi M, Yoshida H, et al. Treatment with vonoprazan for 3\u00a0weeks is not inferior to 8\u00a0weeks for the management of gastric ESD: a multicenter noninferiority randomized study. J Gastroenterol. 2023;58(4):358\u201366.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2422_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5056\/jnm18139","volume":"25","author":"H Mori","year":"2019","unstructured":"Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 2019;25(1):6\u201314.","journal-title":"J Neurogastroenterol Motil"},{"issue":"10","key":"2422_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/10715762.2024.2421174","volume":"58","author":"H Mori","year":"2024","unstructured":"Mori H, Suzuki H. Cutting-edge insights into Helicobacter research. Free Radic Res. 2024;58(10):641\u20137.","journal-title":"Free Radic Res"},{"key":"2422_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.7704\/kjhugr.2025.0091","volume":"26","author":"H Mori","year":"2026","unstructured":"Mori H, Suzuki H. Helicobacter pylori management in older adults: current perspectives from Japan. Korean J Helicobacter Up Gastrointest Res. 2026;26:42\u20139.","journal-title":"Korean J Helicobacter Up Gastrointest Res"},{"issue":"6","key":"2422_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00535-012-0536-9","volume":"47","author":"S Take","year":"2012","unstructured":"Take S, Mizuno M, Ishiki K, Imada T, Okuno T, Yoshida T, et al. Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan. J Gastroenterol. 2012;47(6):641\u20136.","journal-title":"J Gastroenterol"},{"issue":"11-12","key":"2422_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"DR Scott","year":"2015","unstructured":"Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther. 2015;42(11\u201312):1315\u201326.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2422_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","volume":"55","author":"H Echizen","year":"2016","unstructured":"Echizen H. The first-in-class potassium-competitive acid blocker, Vonoprazan Fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(4):409\u201318.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"2422_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by Vonoprazan in comparison with Esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048\u201359.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"2422_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","volume":"13","author":"T Ishizaki","year":"1999","unstructured":"Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on Rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27\u201336.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2422_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/archinte.159.7.649","volume":"159","author":"RH Hunt","year":"1999","unstructured":"Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999;159(7):649\u201357.","journal-title":"Arch Intern Med"},{"issue":"3","key":"2422_CR17","first-page":"301","volume":"69","author":"G Sachs","year":"1996","unstructured":"Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and Helicobacter pylori. Yale J Biol Med. 1996;69(3):301\u201316.","journal-title":"Yale J Biol Med"},{"issue":"6","key":"2422_CR18","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","volume":"167","author":"A Patel","year":"2024","unstructured":"Patel A, Laine L, Moayyedi P, Wu J. AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review. Gastroenterology. 2024;167(6):1228\u201338.","journal-title":"Gastroenterology"},{"issue":"2","key":"2422_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240\u201351.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2422_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","volume":"164","author":"L Laine","year":"2023","unstructured":"Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023;164(1):61\u201371.","journal-title":"Gastroenterology"},{"issue":"2","key":"2422_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S Hoshino","year":"2017","unstructured":"Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, et al. Efficacy of Vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95(2):156\u201361.","journal-title":"Digestion"},{"issue":"14","key":"2422_CR22","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","volume":"24","author":"K Ashida","year":"2018","unstructured":"Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, et al. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24(14):1550\u201361.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"2422_CR23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/CM9.0000000000003068","volume":"137","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Qian J, Zhang S, Dai N, Chun HJ, Chiu C, et al. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: a randomized controlled trial. Chin Med J (Engl). 2024;137(8):962\u201371.","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"2422_CR24","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/apt.15185","volume":"49","author":"KJ Lee","year":"2019","unstructured":"Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7):864\u201372.","journal-title":"Aliment Pharmacol Ther"},{"issue":"19","key":"2422_CR25","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1097\/CM9.0000000000003276","volume":"138","author":"H Zhu","year":"2024","unstructured":"Zhu H, Xue Q, Song Y, Zhang Z, Li X, Lyu S, et al. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: a multicenter, randomized, double-blind, non-inferiority phase III trial. Chin Med J (Engl). 2024;138(19):2464\u201371.","journal-title":"Chin Med J (Engl)"},{"issue":"44","key":"2422_CR26","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.3748\/wjg.v28.i44.6294","volume":"28","author":"KN Lee","year":"2022","unstructured":"Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, et al. Randomized controlled trial to evaluate the efficacy and safety of Fexuprazan compared with Esomeprazole in erosive esophagitis. World J Gastroenterol. 2022;28(44):6294\u2013309.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2422_CR27","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jgh.16471","volume":"39","author":"Q Zhuang","year":"2024","unstructured":"Zhuang Q, Liao A, He Q, Liu C, Zheng C, Li X, et al. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study. J Gastroenterol Hepatol. 2024;39(4):658\u201366.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"2422_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.14309\/ajg.0000000000002929","volume":"120","author":"JH Oh","year":"2025","unstructured":"Oh JH, Kim HS, Cheung DY, Lee HL, Lee DH, Kim GH, et al. Randomized, double-blind, active-controlled phase 3 study to evaluate efficacy and safety of Zastaprazan compared with esomeprazole in erosive esophagitis. Am J Gastroenterol. 2025;120(2):353\u201361.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2422_CR29","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/apt.70109","volume":"61","author":"P Sharma","year":"2025","unstructured":"Sharma P, Vaezi M, Unge P, Andersson K, Larsson K, Popadiyn I, et al. Clinical trial: dose-finding study of Linaprazan Glurate, a novel potassium-competitive acid blocker, versus lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2025;61(10):1590\u2013602.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"2422_CR30","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/apt.16959","volume":"55","author":"S Chen","year":"2022","unstructured":"Chen S, Liu D, Chen H, Liao A, Li F, Liu C, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther. 2022;55(12):1524\u201333.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2422_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14468","volume":"35","author":"J Tack","year":"2023","unstructured":"Tack J, Vladimirov B, Horny I, Chong CF, Eisner J, Czerniak R, et al. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor. Neurogastroenterol Motil. 2023;35(1):e14468.","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"2422_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10388-020-00798-7","volume":"18","author":"H Okanobu","year":"2021","unstructured":"Okanobu H, Kohno T, Mouri R, Hatsushika Y, Yamashita Y, Miyaki E, et al. Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study. Esophagus. 2021;18(3):669\u201375.","journal-title":"Esophagus"},{"issue":"2","key":"2422_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/apt.15062","volume":"49","author":"T Oshima","year":"2019","unstructured":"Oshima T, Arai E, Taki M, Kondo T, Tomita T, Fukui H, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(2):140\u20136.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2422_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41598-024-84065-0","volume":"15","author":"SH Kang","year":"2025","unstructured":"Kang SH, Moon HS, Sung JK, Kim SM, Kim KB, Lee SW, et al. Assessment of the efficacy of on-demand tegoprazan therapy in gastroesophageal reflux disease through a randomized controlled trial. Sci Rep. 2025;15(1):168.","journal-title":"Sci Rep"},{"issue":"1","key":"2422_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5056\/jnm22104","volume":"29","author":"JS Kim","year":"2023","unstructured":"Kim JS, Seo SI, Kang SH, Lee SK, Kim AR, Park HW, et al. Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial. J Neurogastroenterol Motil. 2023;29(1):58\u201364.","journal-title":"J Neurogastroenterol Motil"},{"issue":"1","key":"2422_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5056\/jnm25119","volume":"32","author":"DJ Oh","year":"2026","unstructured":"Oh DJ, Park DH, Jung J, Lim YJ. Comparison of Fexuprazan and Esomeprazole for the control of nocturnal gastroesophageal reflux symptoms: a randomized. Crossover Study J Neurogastroenterol Motil. 2026;32(1):52\u201360.","journal-title":"Crossover Study J Neurogastroenterol Motil"},{"issue":"11","key":"2422_CR37","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000101","volume":"10","author":"Y Kinoshita","year":"2019","unstructured":"Kinoshita Y, Sakurai Y, Takabayashi N, Kudou K, Araki T, Miyagi T, et al. Efficacy and safety of Vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol. 2019;10(11):e00101.","journal-title":"Clin Transl Gastroenterol"},{"issue":"4","key":"2422_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.7704\/kjhugr.2025.0054","volume":"25","author":"YH Kwon","year":"2025","unstructured":"Kwon YH, Kwon JG, Bae JH, Jo HH, Kim EY, Jeon SW, et al. Evaluation of the safety and efficacy of K-CAB (Tegoprazan) as symptomatic maintenance therapy in patients with nerd: a multicenter, randomized double-blinded controlled trial. Korean J Helicobacter Up Gastrointest Res. 2025;25(4):371\u20136.","journal-title":"Korean J Helicobacter Up Gastrointest Res"},{"issue":"4","key":"2422_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000485795","volume":"97","author":"M Umezawa","year":"2018","unstructured":"Umezawa M, Kawami N, Hoshino S, Hoshikawa Y, Koizumi E, Takenouchi N, et al. Efficacy of on-demand therapy using 20-mg Vonoprazan for mild reflux esophagitis. Digestion. 2018;97(4):309\u201315.","journal-title":"Digestion"},{"issue":"1","key":"2422_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13028","volume":"29","author":"T Okimoto","year":"2024","unstructured":"Okimoto T, Ando T, Sasaki M, Ono S, Kobayashi I, Shibayama K, et al. Antimicrobial-resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018\u20132020. Helicobacter. 2024;29(1):e13028.","journal-title":"Helicobacter"},{"key":"2422_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-026-02379-4","author":"H Isomoto","year":"2026","unstructured":"Isomoto H, Shimoyama T, Ito M, Osaki T, Toyoshima O, Matsuzaki J, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition. J Gastroenterol. 2026. https:\/\/doi.org\/10.1007\/s00535-026-02379-4.","journal-title":"J Gastroenterol"},{"issue":"9","key":"2422_CR42","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439\u201346.","journal-title":"Gut"},{"issue":"4","key":"2422_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13125","volume":"29","author":"E Iwata","year":"2024","unstructured":"Iwata E, Sugimoto M, Asaoka D, Hojo M, Ito M, Kitazawa N, et al. Characteristics of Helicobacter pylori eradication therapy in patients 80 years or older living in a metropolitan area: a multicenter retrospective study. Helicobacter. 2024;29(4):e13125.","journal-title":"Helicobacter"},{"key":"2422_CR44","doi-asserted-by":"publisher","first-page":"175628481985851","DOI":"10.1177\/1756284819858511","volume":"12","author":"H Mori","year":"2019","unstructured":"Mori H, Suzuki H, Omata F, Masaoka T, Asaoka D, Kawakami K, et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2019;12:1756284819858511.","journal-title":"Therap Adv Gastroenterol"},{"key":"2422_CR45","doi-asserted-by":"crossref","first-page":"4385161","DOI":"10.1155\/2017\/4385161","volume":"2017","author":"M Maruyama","year":"2017","unstructured":"Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol. 2017;2017:4385161.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"6","key":"2422_CR46","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019\u201326.","journal-title":"Gut"},{"issue":"4","key":"2422_CR47","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/jgh.14456","volume":"34","author":"S Sue","year":"2019","unstructured":"Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019;34(4):686\u201392.","journal-title":"J Gastroenterol Hepatol"},{"key":"2422_CR48","doi-asserted-by":"publisher","DOI":"10.1159\/000546914","author":"S Wasaki","year":"2025","unstructured":"Wasaki S, Mori H, Matsuzaki J, Suzuki H, Hirata K, Imaeda H, et al. Efficacy of vonoprazan-based triple therapy with sitafloxacin and amoxicillin for third-line Helicobacter pylori eradication: a multicenter prospective analysis on drug resistance and gyrA mutations. Dig Dis. 2025;43(5):498-505.","journal-title":"Dig Dis"},{"key":"2422_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122722","author":"T Nishizawa","year":"2021","unstructured":"Nishizawa T, Munkjargal M, Ebinuma H, Toyoshima O, Suzuki H. Sitafloxacin for third-line Helicobacter pylori eradication: a systematic review. J Clin Med.\u00a02021 Jun 20;10(12):2722.","journal-title":"J Clin Med"},{"issue":"15","key":"2422_CR50","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3748\/wjg.v26.i15.1733","volume":"26","author":"H Mori","year":"2020","unstructured":"Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol. 2020;26(15):1733\u201344.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2422_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12719","volume":"25","author":"Y Hirata","year":"2020","unstructured":"Hirata Y, Yamada A, Niikura R, Shichijo S, Hayakawa Y, Koike K. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: a prospective single-arm study. Helicobacter. 2020;25(5):e12719.","journal-title":"Helicobacter"},{"issue":"1","key":"2422_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/cancers11010116","volume":"11","author":"Y Saito","year":"2019","unstructured":"Saito Y, Konno K, Sato M, Nakano M, Kato Y, Saito H, et al. Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori. Cancers (Basel). 2019;11(1):116.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2422_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12900","volume":"27","author":"K Inokuchi","year":"2022","unstructured":"Inokuchi K, Mori H, Matsuzaki J, Hirata K, Harada Y, Saito Y, et al. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen. Helicobacter. 2022;27(4):e12900.","journal-title":"Helicobacter"},{"issue":"2","key":"2422_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15020434","volume":"15","author":"H Mori","year":"2026","unstructured":"Mori H, Saito Y, Ando H, Masaoka T, Matsuzaki J, Nakano M, et al. Third-line and later susceptibility-guided Helicobacter pylori eradication therapies: a multicenter study of vonoprazan\u2013amoxicillin\u2013sitafloxacin\/rifabutin regimens. J Clin Med. 2026;15(2):434.","journal-title":"J Clin Med"},{"issue":"9","key":"2422_CR55","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.31557\/APJCP.2025.26.9.3127","volume":"26","author":"K Suzuki","year":"2025","unstructured":"Suzuki K, Fujimoto A, Mori H, Igarashi Y, Matsuda T. Characteristics of successful third-line eradication of Helicobacter pylori based on antibiotic susceptibility. Asian Pac J Cancer Prev. 2025;26(9):3127\u201331.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"2422_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12592","volume":"24","author":"JH Lee","year":"2019","unstructured":"Lee JH, Ahn JY, Choi KD, Jung HY, Kim JM, Baik GH, et al. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study. Helicobacter. 2019;24(4):e12592.","journal-title":"Helicobacter"},{"issue":"1","key":"2422_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70106","volume":"31","author":"JY Park","year":"2026","unstructured":"Park JY, Hong SJ, Choi IJ, Baik GH, Kim SM, Park JJ, et al. Tegoprazan-based triple therapy for Helicobacter pylori eradication: a phase iii multicenter randomized clinical trial. Helicobacter. 2026;31(1):e70106.","journal-title":"Helicobacter"},{"issue":"5","key":"2422_CR58","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5009\/gnl250067","volume":"19","author":"JY Park","year":"2025","unstructured":"Park JY, Choi IJ, Kim GH, Hong SJ, Shin SK, Jeon SW, et al. Comparative efficacy of potassium-competitive acid blocker-based triple therapy with tegoprazan versus vonoprazan for Helicobacter pylori eradication: a randomized, double-blind, active-controlled pilot study. Gut Liver. 2025;19(5):696\u2013705.","journal-title":"Gut Liver"},{"issue":"2","key":"2422_CR59","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7704\/kjhugr.2024.0012","volume":"24","author":"S Kang","year":"2024","unstructured":"Kang S, Kim NH, Jeong S, Kim JW, Moon JR, Lee YS, et al. Comparison of Tegoprazan- and lansoprazole-based fourteen-day triple therapies as first-line treatments for Helicobacter pylori eradication. Korean J Helicobacter Up Gastrointest Res. 2024;24(2):168\u201374.","journal-title":"Korean J Helicobacter Up Gastrointest Res"},{"issue":"4","key":"2422_CR60","doi-asserted-by":"publisher","first-page":"535","DOI":"10.5009\/gnl220055","volume":"16","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Lee YC, Kim JM, Kim JI, Moon JS, Lim YJ, et al. Triple Therapy-based on Tegoprazan, a new Potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, phase III. Clinical Trial Gut Liver. 2022;16(4):535\u201346.","journal-title":"Clinical Trial Gut Liver"},{"issue":"3","key":"2422_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12977","volume":"28","author":"JS Kim","year":"2023","unstructured":"Kim JS, Ko W, Chung JW, Kim TH. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: a randomized, double-blind, active-controlled study. Helicobacter. 2023;28(3):e12977.","journal-title":"Helicobacter"},{"issue":"5","key":"2422_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13143","volume":"29","author":"JW Lee","year":"2024","unstructured":"Lee JW, Kim N, Lee J, Jo SY, Lee DH. Efficacy of tegoprazan-containing sequential eradication treatment compared to esomeprazole-containing sequential eradication of Helicobacter pylori in South Korea, a region with high antimicrobial resistance: a prospective, randomized, single tertiary center study. Helicobacter. 2024;29(5):e13143.","journal-title":"Helicobacter"},{"issue":"7","key":"2422_CR63","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/pathogens11070786","volume":"11","author":"J Chen","year":"2022","unstructured":"Chen J, Li P, Huang Y, Guo Y, Ding Z, Lu H. Primary antibiotic resistance of Helicobacter pylori in different regions of china: a systematic review and meta-analysis. Pathogens. 2022;11(7):786.","journal-title":"Pathogens"},{"issue":"2","key":"2422_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70112","volume":"31","author":"JY Zhang","year":"2026","unstructured":"Zhang JY, Li J, Huang WF, Lei XY, Huang YL, Xu GH, et al. Efficacy and safety of vonoprazan-based dual, triple, and quadruple therapies for Helicobacter pylori eradication: a randomized controlled trial. Helicobacter. 2026;31(2):e70112.","journal-title":"Helicobacter"},{"issue":"3","key":"2422_CR65","doi-asserted-by":"publisher","first-page":"295","DOI":"10.15403\/jgld-6183","volume":"34","author":"YB Qi","year":"2025","unstructured":"Qi YB, Li XT, Shao QQ, Xu L, Zhang WJ, Song SB, et al. Vonoprazan-containing dual and triple therapies are Non-inferior to Bismuth-quadruple therapy for Helicobacter pylori eradication: a single-center, prospective, open-label. Real-World Study J Gastrointestin Liver Dis. 2025;34(3):295\u2013303.","journal-title":"Real-World Study J Gastrointestin Liver Dis"},{"issue":"5","key":"2422_CR66","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13133","volume":"29","author":"KS Cheung","year":"2024","unstructured":"Cheung KS, Lyu T, Deng Z, Han S, Ni L, Wu J, et al. Vonoprazan dual or triple therapy versus bismuth-quadruple therapy as first-line therapy for Helicobacter pylori infection: a three-arm, randomized clinical trial. Helicobacter. 2024;29(5):e13133.","journal-title":"Helicobacter"},{"issue":"4","key":"2422_CR67","doi-asserted-by":"publisher","first-page":"655","DOI":"10.14309\/ajg.0000000000002592","volume":"119","author":"TL Yan","year":"2024","unstructured":"Yan TL, Wang JH, He XJ, Zhu YB, Lu LJ, Wang YJ, et al. Ten-Day Vonoprazan-Amoxicillin dual therapy vs standard 14-day bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial. Am J Gastroenterol. 2024;119(4):655\u201361.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2422_CR68","doi-asserted-by":"publisher","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","volume":"118","author":"HS Qian","year":"2023","unstructured":"Qian HS, Li WJ, Dang YN, Li LR, Xu XB, Yuan L, et al. Ten-Day Vonoprazan-Amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol. 2023;118(4):627\u201334.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2422_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13151","volume":"29","author":"X Lin","year":"2024","unstructured":"Lin X, Huang H, Liu Y, Zeng Y, Lu S, Xu X, et al. Tegoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: a prospective, randomized, multicenter study in Fujian, China. Helicobacter. 2024;29(6):e13151.","journal-title":"Helicobacter"},{"key":"2422_CR70","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251391276","volume":"18","author":"J Yang","year":"2025","unstructured":"Yang J, Zhang X, Yang L, Wu R, Fan H, Xie N, et al. Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China. Therap Adv Gastroenterol. 2025;18:17562848251391276.","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"2422_CR71","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jgh.70180","volume":"41","author":"Y Fan","year":"2026","unstructured":"Fan Y, Li C, Zhang W, Shi J, Liang R, Deng M, et al. Fourteen-and ten-day Tegoprazan-Amoxicillin dual therapy vs. Bismuth Quadruple therapy for Helicobacter pylori eradication-a noninferiority, multicenter. Randomized Controlled Trial J Gastroenterol Hepatol. 2026;41(2):657\u201366.","journal-title":"Randomized Controlled Trial. J Gastroenterol Hepatol."},{"issue":"1","key":"2422_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70100","volume":"31","author":"S Wei","year":"2026","unstructured":"Wei S, Huang Z, Xiong H, Wu J, Mei D, Zhao J, et al. Efficacy and safety of Keverprazan-Amoxicillin dual regimen in initial eradication of Helicobacter pylori infection: a multicenter, randomized controlled trial. Helicobacter. 2026;31(1):e70100.","journal-title":"Helicobacter"},{"issue":"5","key":"2422_CR73","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70070","volume":"30","author":"Z Song","year":"2025","unstructured":"Song Z, Zuo X, Zhang Z, Wang X, Lin Y, Li Y, et al. Ten-day versus 14-day vonoprazan and amoxicillin dual therapy for the firstline eradication of Helicobacter pylori infection: a multicenter, randomized controlled trial. Helicobacter. 2025;30(5):e70070.","journal-title":"Helicobacter"},{"issue":"12","key":"2422_CR74","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1111\/jgh.16761","volume":"39","author":"A Lin","year":"2024","unstructured":"Lin A, Lin Z, Liu Y, Chen S, Shao Y, Qiu F, et al. Ten-day versus 14-day vonoprazan-amoxicillin high-dose dual therapy for Helicobacter pylori eradication in China: A multicenter, open-label, randomized study. J Gastroenterol Hepatol. 2024;39(12):2645\u201353.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"2422_CR75","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.cgh.2024.01.022","volume":"22","author":"X Peng","year":"2024","unstructured":"Peng X, Yao JY, Ma YQ, Li GH, Chen HW, Wan Y, et al. Efficacy and safety of vonoprazan-amoxicillin dual regimen with varying dose and duration for Helicobacter pylori eradication: a multicenter, prospective, randomized study. Clin Gastroenterol Hepatol. 2024;22(6):1210\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"47","key":"2422_CR76","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i47.114377","volume":"31","author":"CQ Wu","year":"2025","unstructured":"Wu CQ, Zhou X, Li CP, He QL, Chen ZH, Ding SB, et al. Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for Helicobacter pylori eradication in Sichuan Province, China. World J Gastroenterol. 2025;31(47):114377.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2422_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100975","volume":"6","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhang ZY, Wang F, Zhuang K, Xu X, Liu DS, et al. Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025;6(3):100975.","journal-title":"Lancet Microbe"},{"issue":"3","key":"2422_CR78","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","volume":"39","author":"T Furuta","year":"2010","unstructured":"Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am. 2010;39(3):465\u201380.","journal-title":"Gastroenterol Clin North Am"},{"issue":"12","key":"2422_CR79","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00535-023-02042-2","volume":"58","author":"YY Han","year":"2023","unstructured":"Han YY, Zhou L, Hu YL, Ding XW, Long H, Liu F, et al. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study. J Gastroenterol. 2023;58(12):1167\u201377.","journal-title":"J Gastroenterol"},{"issue":"3","key":"2422_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13098","volume":"29","author":"Q Kong","year":"2024","unstructured":"Kong Q, Mirza IA, Zhang X, Song X, Li X, Zhang Q, et al. Fourteen-Day Tegoprazan-Amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection (SHARE2301): a multicenter, noninferiority, randomized clinical trial. Helicobacter. 2024;29(3):e13098.","journal-title":"Helicobacter"},{"issue":"4","key":"2422_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13129","volume":"29","author":"YT Chiu","year":"2024","unstructured":"Chiu YT, Lee FJ, Kuo CY, Chen YT, Lin YC, Liang KS, et al. Seven-day vonoprazan-based triple therapy as first-line Helicobacter pylori treatment in comparison with extended sequential therapy: a randomized controlled trial. Helicobacter. 2024;29(4):e13129.","journal-title":"Helicobacter"},{"issue":"1","key":"2422_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-27876-z","volume":"15","author":"S Sukkamolsantiporn","year":"2025","unstructured":"Sukkamolsantiporn S, Bongkotvirawan P, Chonprasertsuk S, Pornthisarn B, Siramolpiwat S, Bhanthumkomol P, et al. Efficacy of fourteen-day once-daily vonoprazan-based quadruple therapy for Helicobacter pylori in high clarithromycin-resistance regions (ONCE-VONO Trial). Sci Rep. 2025;15(1):44105.","journal-title":"Sci Rep"},{"issue":"6","key":"2422_CR83","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13019","volume":"28","author":"S Ratana-Amornpin","year":"2023","unstructured":"Ratana-Amornpin S, Sanglutong L, Eiamsitrakoon T, Siramolpiwat S, Graham DY, Mahachai V. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023;28(6):e13019.","journal-title":"Helicobacter"},{"issue":"12","key":"2422_CR84","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1111\/jgh.15700","volume":"36","author":"C Bunchorntavakul","year":"2021","unstructured":"Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol. 2021;36(12):3308\u201313.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"2422_CR85","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/apt.17070","volume":"56","author":"D Ang","year":"2022","unstructured":"Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, et al. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther. 2022;56(3):436\u201349.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2422_CR86","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey WD, Megraud F, Laine L, Lopez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608\u201319.","journal-title":"Gastroenterology"},{"issue":"5","key":"2422_CR87","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70083","volume":"30","author":"SA Lashen","year":"2025","unstructured":"Lashen SA, Shamseyea MM, Metwally RH, Abou-Farrag G, Elkaragy ES. Vonoprazan-based triple therapy versus Esomeprazole-based triple therapy for H. pylori eradication in adolescents (VONTAPE): a randomized, double-blind controlled trial. Helicobacter. 2025;30(5):e70083.","journal-title":"Helicobacter"},{"issue":"1","key":"2422_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-98606-8","volume":"15","author":"YM Shekeban","year":"2025","unstructured":"Shekeban YM, Hamdy NA, Header DA, Ahmed SM, Helmy MM. Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial. Sci Rep. 2025;15(1):15989.","journal-title":"Sci Rep"},{"issue":"3","key":"2422_CR89","doi-asserted-by":"publisher","first-page":"432","DOI":"10.47391\/JPMA.9545","volume":"74","author":"F Waqar","year":"2024","unstructured":"Waqar F, Noor M, Haider E, Farhat K, Ali S, Fatime Gilani SF. Therapeutic efficacy and drug safety comparison of one-week vonoprazan triple therapy with two-weeks esomeprazole triple therapy in Helicobacter pylori infection: findings from a single-centre randomized clinical trial in population of Pakistan. J Pak Med Assoc. 2024;74(3):432\u20135.","journal-title":"J Pak Med Assoc"},{"issue":"Suppl 1)(4)","key":"2422_CR90","first-page":"S746","volume":"35","author":"F Waqar","year":"2023","unstructured":"Waqar F, Noor M, Farhat K, Ali S, Haider E, Fatima Gillani SF. Efficacy and cost-effectiveness, comparison of 7-days Vonoprazan versus 14-days Esomeprazole based triple therapies for treating Helicobacter pylori infection in Pakistani population: a randomized clinical trial. J Ayub Med Coll Abbottabad. 2023;35(Suppl 1)(4)):S746\u201351.","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"1","key":"2422_CR91","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12876-021-01822-5","volume":"21","author":"D Kawai","year":"2021","unstructured":"Kawai D, Takenaka R, Ishiguro M, Okanoue S, Gotoda T, Kono Y, et al. Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial. BMC Gastroenterol. 2021;21(1):236.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"2422_CR92","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1177\/0300060519828514","volume":"47","author":"H Komori","year":"2019","unstructured":"Komori H, Ueyama H, Nagahara A, Akazawa Y, Takeda T, Matsumoto K, et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. J Int Med Res. 2019;47(4):1441\u201352.","journal-title":"J Int Med Res"},{"issue":"2","key":"2422_CR93","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2169\/internalmedicine.1146-18","volume":"58","author":"T Ichida","year":"2019","unstructured":"Ichida T, Ueyama S, Eto T, Kusano F, Sakai Y. Randomized controlled trial comparing the effects of vonoprazan plus rebamipide and esomeprazole plus rebamipide on gastric ulcer healing induced by endoscopic submucosal dissection. Intern Med. 2019;58(2):159\u201366.","journal-title":"Intern Med"},{"issue":"4","key":"2422_CR94","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s10620-018-4948-0","volume":"63","author":"A Hirai","year":"2018","unstructured":"Hirai A, Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S, et al. Comparison of the effects of Vonoprazan and lansoprazole for treating endoscopic submucosal dissection-induced artificial ulcers. Dig Dis Sci. 2018;63(4):974\u201381.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"2422_CR95","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5009\/gnl230242","volume":"18","author":"BW Kim","year":"2024","unstructured":"Kim BW, Park JJ, Moon HS, Lee WS, Shim KN, Baik GH, et al. The effect of tegoprazan on the treatment of endoscopic resection-induced artificial ulcers: a multicenter, randomized, active-controlled study. Gut Liver. 2024;18(2):257\u201364.","journal-title":"Gut Liver"},{"issue":"3","key":"2422_CR96","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/17474124.2020.1731304","volume":"14","author":"H Gao","year":"2020","unstructured":"Gao H, Li L, Zhang C, Tu J, Geng X, Wang J, et al. Comparison of efficacy of pharmacological therapies for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and network meta-analysis. Expert Rev Gastroenterol Hepatol. 2020;14(3):207\u201320.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"2422_CR97","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00535-018-1487-6","volume":"54","author":"K Hamada","year":"2019","unstructured":"Hamada K, Uedo N, Tonai Y, Arao M, Suzuki S, Iwatsubo T, et al. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. J Gastroenterol. 2019;54(2):122\u201330.","journal-title":"J Gastroenterol"},{"issue":"5","key":"2422_CR98","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/den.12857","volume":"29","author":"I Tsuchiya","year":"2017","unstructured":"Tsuchiya I, Kato Y, Tanida E, Masui Y, Kato S, Nakajima A, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial. Dig Endosc. 2017;29(5):576\u201383.","journal-title":"Dig Endosc"},{"issue":"8","key":"2422_CR99","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/jgh.17027","volume":"40","author":"H Shibata","year":"2025","unstructured":"Shibata H, Fujiyoshi T, Kawata N, Obayashi T, Esaki M, Kikuchi M, et al. Vonoprazan or proton pump inhibitor for gastric endoscopic submucosal dissection in patients taking antithrombotic agents. J Gastroenterol Hepatol. 2025;40(8):1890\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2422_CR100","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/jgh.15837","volume":"37","author":"X Hou","year":"2022","unstructured":"Hou X, Meng F, Wang J, Sha W, Chiu CT, Chung WC, et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. J Gastroenterol Hepatol. 2022;37(7):1275\u201383.","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"2422_CR101","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00535-019-01587-5","volume":"54","author":"K Sugawara","year":"2019","unstructured":"Sugawara K, Koizumi S, Horikawa Y, Mimori N, Tsuji T, Ishii H, et al. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan. J Gastroenterol. 2019;54(11):963\u201371.","journal-title":"J Gastroenterol"},{"issue":"2","key":"2422_CR102","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13876","volume":"45","author":"H Miwa","year":"2017","unstructured":"Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers\u2014results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45(2):240\u201352.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"2422_CR103","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1080\/03007995.2024.2414090","volume":"40","author":"Y Zong","year":"2024","unstructured":"Zong Y, Lan C, Li X, Chen W, Chen H, Liao A, et al. Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study. Curr Med Res Opin. 2024;40(11):1855\u201362.","journal-title":"Curr Med Res Opin"},{"key":"2422_CR104","doi-asserted-by":"publisher","DOI":"10.5009\/gnl250334","author":"KS Park","year":"2026","unstructured":"Park KS, Kim HS, Oh JH, Chung WC, Choi SC, Lee SH, et al. Randomized, double-blind, active-controlled, parallel, phase 3 clinical trial for evaluating the efficacy and safety of Zastaprazan in patients with gastric ulcers. Gut Liver. 2026. https:\/\/doi.org\/10.5009\/gnl250334.","journal-title":"Gut Liver"},{"issue":"6","key":"2422_CR105","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","volume":"67","author":"T Kawai","year":"2018","unstructured":"Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67(6):1033\u201341.","journal-title":"Gut"},{"issue":"6","key":"2422_CR106","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","volume":"67","author":"Y Mizokami","year":"2018","unstructured":"Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67(6):1042\u201351.","journal-title":"Gut"},{"issue":"5","key":"2422_CR107","doi-asserted-by":"publisher","first-page":"685","DOI":"10.5009\/gnl250019","volume":"19","author":"S Hong","year":"2025","unstructured":"Hong S, Ju JH, Lee SH, Hong SJ, Kim SH, Ahn GY, et al. Comparing the efficacy and safety of fexuprazan and lansoprazole for the prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer. Gut Liver. 2025;19(5):685\u201395.","journal-title":"Gut Liver"},{"issue":"4","key":"2422_CR108","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1053\/j.gastro.2024.03.036","volume":"167","author":"T Geeratragool","year":"2024","unstructured":"Geeratragool T, Kaosombatwattana U, Boonchote A, Chatthammanat S, Preechakawin N, Srichot J, et al. Comparison of Vonoprazan versus intravenous proton pump inhibitor for prevention of high-risk peptic ulcers rebleeding after successful endoscopic hemostasis: a multicenter randomized noninferiority trial. Gastroenterology. 2024;167(4):778-87.e3.","journal-title":"Gastroenterology"},{"issue":"6","key":"2422_CR109","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1053\/j.gastro.2026.01.038","volume":"170","author":"H T\u00f6rnblom","year":"2026","unstructured":"T\u00f6rnblom H, Carbone F, Hasler WL, Smout A, Suzuki H, Tack J, et al. Gastroduodenal Disorders. Gastroenterology. 2026;170(6):1240\u201360.","journal-title":"Gastroenterology"},{"issue":"6","key":"2422_CR110","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1053\/j.gastro.2016.02.011","volume":"150","author":"V Stanghellini","year":"2016","unstructured":"Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380\u201392.","journal-title":"Gastroenterology"},{"issue":"3","key":"2422_CR111","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/apt.70189","volume":"62","author":"J Tack","year":"2025","unstructured":"Tack J, Palsson OS, Bangdiwala SI, Schol J, Carbone F, Van Den Houte K, et al. Functional dyspepsia and its subgroups: prevalence and impact in the Rome IV global epidemiology study. Aliment Pharmacol Ther. 2025;62(3):330\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2422_CR112","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000532082","volume":"105","author":"T Oshima","year":"2024","unstructured":"Oshima T. Functional dyspepsia: current understanding and future perspective. Digestion. 2024;105(1):26\u201333.","journal-title":"Digestion"},{"key":"2422_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.851012","volume":"16","author":"L Wauters","year":"2022","unstructured":"Wauters L, Ceulemans M, Schol J, Farre R, Tack J, Vanuytsel T. The role of leaky gut in functional dyspepsia. Front Neurosci. 2022;16:851012.","journal-title":"Front Neurosci"},{"issue":"10","key":"2422_CR114","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14262","volume":"33","author":"L Wauters","year":"2021","unstructured":"Wauters L, Ceulemans M, Vanuytsel T. Duodenum at a crossroads: key integrator of overlapping and psychological symptoms in functional dyspepsia? Neurogastroenterol Motil. 2021;33(10):e14262.","journal-title":"Neurogastroenterol Motil"},{"key":"2422_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2022.170905","volume":"160","author":"H Mori","year":"2023","unstructured":"Mori H, Verbeure W, Tanemoto R, Sosoranga ER, Jan T. Physiological functions and potential clinical applications of motilin. Peptides. 2023;160:170905.","journal-title":"Peptides"},{"issue":"7","key":"2422_CR116","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/ajg.2017.154","volume":"112","author":"P Moayyedi","year":"2017","unstructured":"Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112(7):988\u20131013.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2422_CR117","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/br.2016.828","volume":"6","author":"D Asaoka","year":"2017","unstructured":"Asaoka D, Nagahara A, Hojo M, Matsumoto K, Ueyama H, Matsumoto K, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep. 2017;6(2):175\u201380.","journal-title":"Biomed Rep"},{"issue":"12","key":"2422_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70082","volume":"8","author":"C Bunchorntavakul","year":"2024","unstructured":"Bunchorntavakul C, Jaigla P. Efficacy of vonoprazan 10\u2009mg and 20\u2009mg for patients with proton pump inhibitor-refractory functional dyspepsia: a double-blinded, randomized study. JGH Open. 2024;8(12):e70082.","journal-title":"JGH Open"},{"issue":"9","key":"2422_CR119","volume":"16","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Futagami S, Agawa S, Higashida S, Onda T, Kawawa R, et al. Long-term Vonoprazan and Acotiamide-refractory patients with functional dyspepsia partly exhibit pancreatic enzyme abnormalities. Cureus. 2024;16(9):e70371.","journal-title":"Cureus"},{"issue":"3","key":"2422_CR120","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5056\/jnm23150","volume":"30","author":"CW Huh","year":"2024","unstructured":"Huh CW, Youn YH, Jung DH, Cha RR, Kim YJ, Jung K, et al. Efficacy of Tegoprazan in patients with functional dyspepsia: a prospective, multicenter. Single-arm Study J Neurogastroenterol Motil. 2024;30(3):313\u201321.","journal-title":"Single-arm Study J Neurogastroenterol Motil"},{"issue":"3","key":"2422_CR121","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10620-024-08714-0","volume":"70","author":"HS Lim","year":"2025","unstructured":"Lim HS, Yoon HJ, Jung HK, Hong JT, Yoo MY, Jeong ES. Effects of tegoprazan, potassium-competitive acid blocker, on the gastric emptying and postprandial symptoms in healthy humans. Dig Dis Sci. 2025;70(3):1091\u20138.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2422_CR122","doi-asserted-by":"publisher","first-page":"31","DOI":"10.14309\/ajg.0000000000003194","volume":"120","author":"ES Dellon","year":"2025","unstructured":"Dellon ES, Muir AB, Katzka DA, Shah SC, Sauer BG, Aceves SS, et al. ACG clinical guideline: diagnosis and management of eosinophilic esophagitis. J Am Gastroenterol. 2025;120(1):31\u201359.","journal-title":"J Am Gastroenterol"},{"issue":"3","key":"2422_CR123","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2050640616689525","volume":"5","author":"AJ Lucendo","year":"2017","unstructured":"Lucendo AJ, Molina-Infante J, Arias \u00c1, von Arnim U, Bredenoord AJ, Bussmann C, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5(3):335\u201358.","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"2422_CR124","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s10388-020-00783-0","volume":"18","author":"T Kuzumoto","year":"2021","unstructured":"Kuzumoto T, Tanaka F, Sawada A, Nadatani Y, Otani K, Hosomi S, et al. Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis. Esophagus. 2021;18(2):372\u20139.","journal-title":"Esophagus"},{"issue":"4","key":"2422_CR125","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MCG.0000000000001869","volume":"58","author":"Y Fujiwara","year":"2024","unstructured":"Fujiwara Y, Sawada A, Ominami M, Fukunaga S, Otani K, Hosomi S, et al. Responses of proton pump inhibitors and potassium-competitive acid blockers according to outcomes of symptom, endoscopy, and histology in patients with eosinophilic esophagitis. J Clin Gastroenterol. 2024;58(4):337\u201341.","journal-title":"J Clin Gastroenterol"},{"key":"2422_CR126","first-page":"1","volume":"4","author":"Y Fujiwara","year":"2026","unstructured":"Fujiwara Y, Sawada A, Hosomi S, Tanaka F. Differences in adult eosinophilic esophagitis between Japan and Western countries. J Gastroenterol. 2026;4:1\u20138.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2422_CR127","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jgh.70178","volume":"41","author":"Y Jang","year":"2026","unstructured":"Jang Y, Park J, Kang D, Kim JH, Choi HS, Jeon HL, et al. Safety of potassium-competitive acid blockers compared with proton pump inhibitors in patients with gastroesophageal reflux disease and peptic ulcer disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2026;41(1):28\u201340.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2422_CR128","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706\u201315.","journal-title":"Gastroenterology"},{"issue":"7","key":"2422_CR129","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/ajg.2012.179","volume":"107","author":"S Janarthanan","year":"2012","unstructured":"Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2422_CR130","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.amjmed.2011.01.007","volume":"124","author":"EW Yu","year":"2011","unstructured":"Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124(6):519\u201326.","journal-title":"Am J Med"},{"issue":"2","key":"2422_CR131","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238\u201346.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2422_CR132","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s00535-010-0207-7","volume":"45","author":"M Hongo","year":"2010","unstructured":"Hongo M, Fujimoto K. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45(6):618\u201324.","journal-title":"J Gastroenterol"},{"issue":"10","key":"2422_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153113","volume":"216","author":"A Tatsuguchi","year":"2020","unstructured":"Tatsuguchi A, Hoshino S, Kawami N, Gudis K, Nomura T, Shimizu A, et al. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa. Pathol Res Pract. 2020;216(10):153113.","journal-title":"Pathol Res Pract"},{"key":"2422_CR134","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819834511","volume":"12","author":"KS Cheung","year":"2019","unstructured":"Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019;12:1756284819834511.","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"2422_CR135","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740\u20138.","journal-title":"Gut"},{"issue":"4","key":"2422_CR136","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1365-2362.2010.02419.x","volume":"41","author":"D Compare","year":"2011","unstructured":"Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011;41(4):380\u20136.","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"2422_CR137","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","volume":"73","author":"W Gomm","year":"2016","unstructured":"Gomm W, von Holt K, Thom\u00e9 F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410\u20136.","journal-title":"JAMA Neurol"},{"issue":"6","key":"2422_CR138","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015735","volume":"7","author":"Y Xie","year":"2017","unstructured":"Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735.","journal-title":"BMJ Open"},{"issue":"5","key":"2422_CR139","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2024.08.004","volume":"23","author":"N Uemura","year":"2025","unstructured":"Uemura N, Kinoshita Y, Haruma K, Kushima R, Yao T, Akiyama J, et al. Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study. Clin Gastroenterol Hepatol. 2025;23(5):748-57.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2422_CR140","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12876-023-02772-w","volume":"23","author":"K Haruma","year":"2023","unstructured":"Haruma K, Kinoshita Y, Yao T, Kushima R, Akiyama J, Aoyama N, et al. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of Vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterol. 2023;23(1):139.","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"2422_CR141","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1080\/00365521.2022.2097893","volume":"57","author":"S Shinozaki","year":"2022","unstructured":"Shinozaki S, Osawa H, Miura Y, Hayashi Y, Sakamoto H, Yano T, et al. Long-term changes in serum gastrin levels during standard dose Vonoprazan therapy. Scand J Gastroenterol. 2022;57(12):1412\u20136.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"2422_CR142","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cgh.2024.01.037","volume":"22","author":"J Arai","year":"2024","unstructured":"Arai J, Miyawaki A, Aoki T, Niikura R, Hayakawa Y, Fujiwara H, et al. Association between Vonoprazan and the risk of gastric cancer after Helicobacter pylori eradication. Clin Gastroenterol Hepatol. 2024;22(6):1217-25.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2422_CR143","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10120-025-01702-x","volume":"29","author":"Y Shiratori","year":"2026","unstructured":"Shiratori Y, Kim Y, Fukuda K, Suzuki N, Hayakawa Y, Tsuji Y, et al. Long-term use of potassium-competitive acid blockers and proton pump inhibitors and the risk of metachronous gastric cancer after H. pylori eradication: a multicenter cohort study. Gastric Cancer. 2026;29(2):347\u201356.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2422_CR144","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","volume":"67","author":"KS Cheung","year":"2018","unstructured":"Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28\u201335.","journal-title":"Gut"},{"issue":"4","key":"2422_CR145","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12597","volume":"24","author":"M Kato","year":"2019","unstructured":"Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter. 2019;24(4):e12597.","journal-title":"Helicobacter"},{"issue":"7","key":"2422_CR146","doi-asserted-by":"publisher","first-page":"547","DOI":"10.7326\/0003-4819-129-7-199810010-00007","volume":"129","author":"L Laine","year":"1998","unstructured":"Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med. 1998;129(7):547\u201350.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2422_CR147","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1017\/S0954422407334082","volume":"19","author":"P Guilloteau","year":"2006","unstructured":"Guilloteau P, Le Meuth-Metzinger V, Morisset J, Zabielski R. Gastrin, cholecystokinin and gastrointestinal tract functions in mammals. Nutr Res Rev. 2006;19(2):254\u201383.","journal-title":"Nutr Res Rev"},{"issue":"2-3","key":"2422_CR148","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000106453","volume":"75","author":"TK Cheung","year":"2007","unstructured":"Cheung TK, Wong WM, Wong NYH, Chan CK, Fung J, Yuen MF, et al. Symptom resolution does not predict healing of erosive oesophagitis in Chinese. Digestion. 2007;75(2\u20133):128\u201334.","journal-title":"Digestion"},{"issue":"4","key":"2422_CR149","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s10620-006-9415-7","volume":"52","author":"T Hagiwara","year":"2007","unstructured":"Hagiwara T, Mukaisho K, Ling ZQ, Sakano T, Sugihara H, Hattori T. Rebamipide contributes to reducing adverse effects of long-term administration of Omeprazole in rats. Dig Dis Sci. 2007;52(4):988\u201394.","journal-title":"Dig Dis Sci"},{"key":"2422_CR150","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003943","author":"KL Karlin","year":"2026","unstructured":"Karlin KL, Gilbert EH, Lim F, Agyekum AA, Yang JY, Faye AS, et al. Proton pump inhibitors are more cost-effective than potassium competitive acid blockers for gastroesophageal reflux disease. Am J Gastroenterol. 2026. https:\/\/doi.org\/10.14309\/ajg.0000000000003943.","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02422-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02422-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02422-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:07:14Z","timestamp":1787670434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02422-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":150,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2422"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02422-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hidekazu Suzuki has received research funding from Tohso Co., Ltd., and honoraria from Astellas Pharmaceutical Company, Otsuka Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Hideki Mori declares no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}